Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(4):304-308
DOI: 10.5428/pcar20190417
Evaluation of rational use of Danhong injection from the perspective of contraindications
1. XUN Zhikun(Department of Pharmacy,Beijing Electric Power Hospital of State Grid Co. of China,Electric Power Teaching Hospital of Capital Medical University,Beijing 100073,China xunzhikun@139.com)
2. JIA Lihua(Department of Pharmacy,Beijing Electric Power Hospital of State Grid Co. of China,Electric Power Teaching Hospital of Capital Medical University,Beijing 100073,China )
3. LI Zhongdong(Department of Pharmacy,Beijing Electric Power Hospital of State Grid Co. of China,Electric Power Teaching Hospital of Capital Medical University,Beijing 100073,China zhdl009@126.com)
ABSTRACT  Objective:To evaluate the rationality of clinical use of Danhong injection from the perspective of contraindications,and provide reference for the evaluation of similar traditional Chinese medicines for promoting blood circulation and relieving blood stasis.Methods:Retrospective matching method was used in the study.Two hundred cases treated with Danhong injection and 120 cases not treated with Danhong injection from March,2017 to April,2018 in Beijing Electric Power Hospital of State Grid were randomly selected for the study.The bleeding risks and grades of patients with ischemic stroke and coronary heart diseases were evaluated using S2TOP-BLEED scores and CRUSADE scores,respectively.Then,an investigation was also made on the hemorrhage of the bleeding patients with various grades. Results: In the 200 patients treated with Danhong injection,13 developed hemorrhage,of whom 7 were evaluated as high risk patients by S2TOP-BLEED scores,and 6 were evaluated as high risk patients by CRUSADE scores,with the rate of hemorrhage,accounting for 6.5% (13/200).Of the 120 patients without treatment of Danhong injection,only 1 patient had hemorrhage evaluated as extremely high risk patients by CRUSADE scores,with the rate of hemorrhage accounting for 0.8% (1/120).Those patients evaluated as extremely high risk ones were all treated with at least one kind of anticoagulant or antiplatelet drugs.Conclusion: For the ischemic stroke patients evaluated as high risk ones by S2TOP-BLEED scores and those coronary heart disease patients evaluated as extremely high risk patients and treated with anticoagulant or antiplatelet drugs,the use of Danhong injection should be avoided if signs of hemorrhage develop.
Welcome to PCAR! You are the number 85 reader of this article!
Please cite this article as:
XUN Zhikun,JIA Lihua,LI Zhongdong,. Evaluation of rational use of Danhong injection from the perspective of contraindications[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 304-308.
References:
1. FENG Liying,LIANG Xiaoling,LI Tingting,et al.Influence of Danhong injection on anticoagulant effect of warfarin in rats in vivo[J].China Pharmacist,2016,19(1):1-4.In Chinese with English abstract.
2. Mehran R,Rao S V,Bhatt D L,et al.Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium[J].Circulation,2011,123(23):2736-2747.
3. ZHANG Qian,JU Wenzheng,GUO Jianming,et al.Rationality analysis of clinical application of Danhong injection in Affiliated Hospital of Nanjing University of Chinese Medicine from 2013 to 2014[J].China J Chin Mater Med,2016,41(4):748-754.In Chinese with English abstract.
4. Tan H K,Baldwin I,Bellomo R.Continuous veno-venous hemofiltration without anticoagulation in high-risk patients[J].Intensive Care Med,2000,26(11):1652-1657.
5. FENG Xiaxia.Application of bleeding score systems in pharmaceutical care for acute coronary syndroome[J].Pharm Care Res,2013,13(2):98-102.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口